TribulosinCAS# 79974-46-2 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 79974-46-2 | SDF | Download SDF |
| PubChem ID | 71312536 | Appearance | Off-white powder |
| Formula | C55H90O25 | M.Wt | 1151.3 |
| Type of Compound | Steroids | Storage | Desiccate at -20°C |
| Solubility | Soluble in DMSO; slightly soluble in water; insoluble in methan | ||
| Chemical Name | (2S,3R,4R,5R,6S)-2-[(2R,3R,4S,5R,6R)-4-hydroxy-5-[(2S,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3,4-bis[[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy]oxan-2-yl]oxy-6-(hydroxymethyl)-2-[(1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S,16S,18S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-16-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol | ||
| SMILES | CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CCC6C5(CCC(C6)OC7C(C(C(C(O7)CO)OC8C(C(C(C(O8)CO)O)OC9C(C(C(CO9)O)O)O)OC2C(C(C(CO2)O)O)O)O)OC2C(C(C(C(O2)C)O)O)O)C)C)C)OC1 | ||
| Standard InChIKey | YYCFEJVBMMGRLX-BTLNAVNBSA-N | ||
| Standard InChI | InChI=1S/C55H90O25/c1-21-8-13-55(71-18-21)22(2)34-31(80-55)15-28-26-7-6-24-14-25(9-11-53(24,4)27(26)10-12-54(28,34)5)73-51-46(78-50-42(67)39(64)35(60)23(3)72-50)43(68)44(33(17-57)75-51)76-52-47(79-49-41(66)37(62)30(59)20-70-49)45(38(63)32(16-56)74-52)77-48-40(65)36(61)29(58)19-69-48/h21-52,56-68H,6-20H2,1-5H3/t21-,22-,23-,24-,25-,26+,27-,28-,29+,30+,31-,32+,33+,34-,35-,36-,37-,38+,39+,40+,41+,42+,43-,44-,45-,46+,47+,48-,49-,50-,51+,52-,53-,54-,55+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Tribulosin protects myocardium against ischemia/reperfusion injury through PKCepsilon activation, it also has protective effects on cardiac myocytes against apoptosis induced by H/R injury via PKCϵ and ERK1/2 signaling pathway. | |||||
Tribulosin Dilution Calculator
Tribulosin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 0.8686 mL | 4.3429 mL | 8.6858 mL | 17.3717 mL | 21.7146 mL |
| 5 mM | 0.1737 mL | 0.8686 mL | 1.7372 mL | 3.4743 mL | 4.3429 mL |
| 10 mM | 0.0869 mL | 0.4343 mL | 0.8686 mL | 1.7372 mL | 2.1715 mL |
| 50 mM | 0.0174 mL | 0.0869 mL | 0.1737 mL | 0.3474 mL | 0.4343 mL |
| 100 mM | 0.0087 mL | 0.0434 mL | 0.0869 mL | 0.1737 mL | 0.2171 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 4-Oxadocosane-1,2-diol
Catalog No.:BCN9887
CAS No.:544-62-7
- 15-Deoxypulic acid
Catalog No.:BCN9886
CAS No.:95523-05-0
- 6-Methoxyflavanone
Catalog No.:BCN9885
CAS No.:3034-04-6
- (1S,2S,5S)-(-)-Myrtanol
Catalog No.:BCN9884
CAS No.:53369-17-8
- 2-(2-Hydroxybenzal)acetophenone
Catalog No.:BCN9883
CAS No.:644-78-0
- gamma-Decalactone
Catalog No.:BCN9882
CAS No.:706-14-9
- 5,7-Dihydroxy 3,3',4',5',6,8-hexamethoxyflavone
Catalog No.:BCN9881
CAS No.:96887-18-2
- Cymarin
Catalog No.:BCN9880
CAS No.:508-77-0
- Dihydroquinine
Catalog No.:BCN9879
CAS No.:522-66-7
- Tricaprin
Catalog No.:BCN9878
CAS No.:621-71-6
- Lyciumamide B
Catalog No.:BCN9877
CAS No.:1647111-41-8
- 4-Hydroxyisophthalic acid
Catalog No.:BCN9876
CAS No.:636-46-4
- Cinnamtannin A2
Catalog No.:BCN9889
CAS No.:86631-38-1
- Tryptamine hydrochloride
Catalog No.:BCN9890
CAS No.:343-94-2
- Caffeoyl alcohol
Catalog No.:BCN9891
CAS No.:3598-26-3
- 5-Geranoxy-7-methoxycoumarin
Catalog No.:BCN9892
CAS No.:7380-39-4
- (-)-Linalool
Catalog No.:BCN9893
CAS No.:126-91-0
- Methyl anthranilate
Catalog No.:BCN9894
CAS No.:134-20-3
- 3-Octanone
Catalog No.:BCN9895
CAS No.:106-68-3
- Decanoic acid
Catalog No.:BCN9896
CAS No.:334-48-5
- 3',4'-Dimethoxyflavone
Catalog No.:BCN9897
CAS No.:4143-62-8
- Dihydroisoferulic acid
Catalog No.:BCN9898
CAS No.:1135-15-5
- cis-Jasmone
Catalog No.:BCN9899
CAS No.:488-10-8
- Methyl benzoate
Catalog No.:BCN9900
CAS No.:93-58-3
Tribulosin suppresses apoptosis via PKC epsilon and ERK1/2 signaling pathway during hypoxia/reoxygenation in neonatal rat ventricular cardiac myocytes.[Pubmed:22115037]
J Asian Nat Prod Res. 2011 Dec;13(12):1135-45.
Tribulosin (tigogenin 3-O-beta-D-xylopyranosyl(1-2)-[beta-D-xylopyranosyl (1-3)]-beta-D-glucopyranosyl (1-4)-[a-L-rhamnopyranosyl(1-2)]-beta-D-galactopyranoside), a component of gross saponins of Tribulus terrestris, has been shown to produce cytoprotective effects in heart. Yet, the precise mechanisms are not fully understood. We examined the mechanisms of Tribulosin on myocardial protection. Ventricular myocytes were isolated from the heart of neonatal rats and were exposed to 3 h of hypoxia followed by 2 h reoxygenation. Apoptosis was induced by hypoxia/reoxygenation (H/R), and the expression of protein kinase C epsilon (PKC) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) in cultured neonatal rat cardiac myocytes was detected. The results indicated that treatment with Tribulosin in the culture medium protected cardiac myocytes against apoptosis induced by H/R. PKC and ERK1/2 expression increased after pretreated with Tribulosin. In the presence of PKC inhibitor co-treated with Tribulosin, the expression of ERK1/2 was decreased in H/R cardiac myocytes. While preconditioned with PD98059, ERK1/2 inhibitor, no effects on the expression of PKC were detected. Tribulosin has protective effects on cardiac myocytes against apoptosis induced by H/R injury via PKC and ERK1/2 signaling pathway.
Tribulosin protects rat hearts from ischemia/reperfusion injury.[Pubmed:20453871]
Acta Pharmacol Sin. 2010 Jun;31(6):671-8.
AIM: To investigate the protective effect of Tribulosin, a monomer of the gross saponins from Tribulus terrestris, against cardiac ischemia/reperfusion injury and the underlying mechanism in rats. METHODS: Isolated rat hearts were subjected to 30 min of ischemia followed by 120 min of reperfusion using Langendorff's technique. The hearts were assigned to seven groups: control, ischemia/reperfusion (I/R), treatment with gross saponins from Tribulus terrestris (GSTT) 100 mg/L, treatment with Tribulosin (100, 10, and 1 nmol/L) and treatment with a PKC inhibitor (chelerythrine) (1 micromol/L). Infarct size was assessed by triphenyltetrazolium chloride staining. Malondialdehyde (MDA), aspartate aminotransferase (AST), and lactate dehydrogenase (LDH) contents as well as superoxide dismutase (SOD) and creatine kinase (CK) activities were determined after the treatment. Histopathological changes in the myocardium were observed using hematoxylin-eosin (H&E) staining. Apoptosis was detected with terminal deoxynucleotidyl transferase nick-end labeling (TUNEL) assay. Bcl-2, Bax, caspase-3, and PKCepsilon protein expression were examined using Western blotting. RESULTS: Tribulosin treatment significantly reduced MDA, AST, CK and LDH contents, and increased the activity of SOD. The infarct size of I/R group was 40.21% of the total area. GSTT and various concentrations of Tribulosin treatment decreased the infarct size to 24.33%, 20.24%, 23.19%, and 30.32% (P<0.01). Tribulosin treatment reduced the myocardial apoptosis rate in a concentration-dependent manner. Bcl-2 and PKCepsilon protein expression was increased after Tribulosin preconditioning, whereas Bax and caspase-3 expression was decreased. In the chelerythrine group, Bcl-2 and PKCepsilon expression was decreased, whereas Bax and caspase-3 expression was increased. CONCLUSION: Tribulosin protects myocardium against ischemia/reperfusion injury through PKCepsilon activation.
Cholestane- and pregnane-type glycosides from the roots of Tribulus cistoides.[Pubmed:8835464]
Phytochemistry. 1996 Feb;41(3):907-17.
From the methanolic extract of the roots of Tribulus cistoides the cardioactive saponin-3, which is known to occur in the leaves, was isolated along with Tribulosin, a pregnane-type glycoside and eight new cholestane glycosides. D-(+)-Pinitol and sucrose were major constituents. The structures were established by spectroscopic studies of the isolated compounds, their acetylated derivatives and their hydrolysation products. Chemical conversions revealed the configurations at C-22 and C-25, respectively.
